Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study
Oralee J Varnado,1 Janna Manjelievskaia,2 Wenyu Ye,1 Allison Perry,2 Kory Schuh,1 Richard Wenzel1 1Value, Evidence, and Outcomes, Eli Lilly and Company, Indianapolis, IN, USA; 2Watson Health Life Sciences, Research & Analytics, IBM Watson Health, Cambridge, MA, USACorrespondence: Oralee J Varnad...
Main Authors: | Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-03-01
|
Series: | Patient Preference and Adherence |
Subjects: | |
Online Access: | https://www.dovepress.com/treatment-patterns-for-calcitonin-gene-related-peptide-monoclonal-anti-peer-reviewed-fulltext-article-PPA |
Similar Items
-
Treatment Patterns, Healthcare Resource Utilization, and Direct Costs Among Patients Initiating Concomitant Use of a Calcitonin Gene-Related Peptide Monoclonal Antibody (CGRP mAb) and Novel Acute Medication in the United States
by: Varnado OJ, et al.
Published: (2023-12-01) -
Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study
by: Varnado OJ, et al.
Published: (2024-01-01) -
Photophobia and migraine outcome during treatment with galcanezumab
by: Francesca Schiano di Cola, et al.
Published: (2023-01-01) -
An Evidence-Based Review of Galcanezumab for the Treatment of Migraine
by: Ivan Urits, et al.
Published: (2020-10-01) -
New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
by: Damiana Scuteri, et al.
Published: (2019-04-01)